Allakos, Inc. is a clinical-stage biotechnology company, which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells, which are involved in allergy, inflammation and tissue damage. Its lead program is AK002, which is an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells, including eosinophilic gastritis (EG), indolent systemic mastocytosis, urticaria and allergic conjunctivitis.
Number of employees : 62 people.
|Vote ||Quantity||Float||Company-owned shares||Total Float
|Alta Partners Management Corp. ||11,519,200||
|RiverVest Venture Management LLC ||6,900,506||
|Capital Research & Management Co. (Global Investors) ||5,059,493||
|Bayer Aktiengesellschaft ||4,610,723||
|NEA Management Co. LLC ||4,536,376||
|Capital Research & Management Co. (World Investors) ||3,494,852||
|Capital Research & Management Co. (International Investors) ||3,408,807||
|Fidelity Management & Research Co. ||3,289,839||
|Redmile Group LLC ||3,077,128||
|The Vanguard Group, Inc. ||2,312,061||
|Company contact information|
Connections : Allakos Inc.